Diacomit FDA Approval History
Last updated by Judith Stewart, BPharm on Sep 26, 2019.
FDA Approved: Yes (First approved August 20, 2018)
Brand name: Diacomit
Generic name: stiripentol
Dosage form: Capsules and Powder for Oral Suspension
Company: Biocodex
Treatment for: Dravet Syndrome
Diacomit (stiripentol) is an anticonvulsant indicated for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older taking clobazam.
Development timeline for Diacomit
| Date | Article |
|---|---|
| Aug 21, 2018 | Approval FDA Approves Diacomit (stiripentol) for Seizures Associated with Dravet Syndrome |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.